Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Intervention With Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome (TMA/aHUS)-Associated Multiple Organ Dysfunction Syndrome (MODS) in Hematopoietic Stem Cell Transplant (HCT) Recipients

NCT03518203 is registered in ClinicalTrials.gov with Children's Hospital Medical Center, Cincinnati as lead sponsor.

NCT NCT03518203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03518203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Intervention With Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome (TMA/aHUS)-Associated Multiple Organ Dysfunction Syndrome (MODS) in Hematopoietic Stem Cell Transplant (HCT) Recipients
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Phase
Phase 2
Overall status
Completed
Start date
August 3, 2018
Completion date
June 1, 2022
Enrollment
23 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atypical hemolytic uremic syndrome, multiple organ dysfunction syndrome, thrombotic microangiopathies